COMMUNIQUÉS West-GlobeNewswire

LifeLabs Celebrates National Medical Laboratory Week Recognizing Compassionate, Passionate, and Innovative Professionals
15/04/2024
Toronto, April 15, 2024 (GLOBE NEWSWIRE) -- This week, LifeLabs joins in celebrating the annual National Medical Laboratory Week, a significant event organized by the Canadian Society for Medical Laboratory Science. [...]
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
15/04/2024
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138 BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
15/04/2024
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) [...]
Novo Nordisk A/S - share repurchase programme
15/04/2024
Bagsværd, Denmark, 15 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Sienna Announces April Dividend
15/04/2024
MARKHAM, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15/04/2024
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral [...]
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)
15/04/2024
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Microbot Medical Shares Status Following Recent Geopolitical Events
15/04/2024
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in [...]
Mobile-health Network Solutions Makes History as First APAC Telehealth Company Listed on US Stock Exchange
15/04/2024
SINGAPORE, April 15, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR ), a pioneering Asia-Pacific (APAC) telehealth provider, celebrates its successful initial public offering (IPO) on the Nasdaq [...]
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15/04/2024
- FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study - - Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in [...]
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria (PNH)
15/04/2024
A Promising Treatment for PNH Patients The United States Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to NM5072 for the treatment of anemia in PNH patients. The ODD provides NM5072 with a [...]
TOMI Environmental Solutions to Attend Interphex 2024
15/04/2024
FREDERICK, Md., April 15, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces attendance at [...]
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
15/04/2024
Marjan Shamsaei, PharmD, Newly Appointed as Senior Vice President, Commercial Development and Portfolio Lead Brings Deep Oncology Product Commercialization Expertise NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO [...]
PetMeds® Announces Fiscal 2024 Third Quarter Financial Results and Completion of Financial Restatement
15/04/2024
Fiscal 2024 3Q Revenue of $65.3 million , an 11% increase compared to last year including PetCareRx results. AutoShip & Save and PetPlus Membership, 52% of total revenue, up from 42% at the same time last year. [...]
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
15/04/2024
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in [...]
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15/04/2024
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER- [...]
Turning dreams into reality: 1970s-inspired Lachine Hospital Foundation Gala raises $182,830 net to support the modernization and expansion of the Lachine Hospital
15/04/2024
The Lachine Hospital Foundation’s signature gala raised $182,830 net, to support the Dream Big: Lachine Hospital campaign, an ongoing collaboration between the Lachine Hospital Foundation and the MUHC Foundation DORVAL [...]
Nos rêves deviennent réalité : le gala de la Fondation de l’Hôpital de Lachine, inspiré des années 1970, permet de recueillir 182 830 $ net, pour soutenir la modernisation et l’agrandissement de l’Hôpital de Lachine.
15/04/2024
Le gala signature de la Fondation de l’Hôpital de Lachine a permis de recueillir 182 830 $ net pour soutenir la campagne Osez rêver pour l’Hôpital de Lachine, une collaboration entre la Fondation de l’Hôpital de Lachine [...]
Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole
15/04/2024
Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients Discontinuations due to drug-related adverse events and drug-drug [...]

Pages